



CSE: IN
OTCQB: IMLFF

Suite 350– 409 Granville ST
Vancouver, BC, Canada V6C-1T2
Tel: 604.669.7207
Email: info@inmedpharma.com
www.inmedpharma.com

InMed to Present at Cannabis-Based Therapies Conference

Vancouver, BC – November 23, 2016 - InMed Pharmaceuticals, Inc. (“InMed”) (CSE: IN; OTCQB: IMLFF), announced today that it will present at the ‘Cannabis-Based Therapies’ medical conference on Wednesday, November 30th and Thursday, December 1st, 2016 at the Hyatt Centric Fisherman’s Warf in San Francisco, CA.

Dr. Sazzad Hossain, InMed’s Chief Scientific Officer, will participate as a panel member during the session entitled “Regulatory Hurdles Impacting Cannabis-Based Research” as well as presenting a case study entitled “Leveraging the Pharmacobiology of Cannabinoid Receptors for Drug Discovery and Pharmaceutical Drug Development”. This presentation will highlight the validation of InMed’s proprietary bioinformatics analysis tool being utilized for drug-disease targeting and expedited pre-clinical testing of new cannabinoid-based drugs.

More information on this conference, organized by CBI - a division of UBM, is available at: www.cbinet.com/cannabistherapies.com

About InMed

InMed is a pre-clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. InMed’s proprietary bioinformatics drug/disease targeting tool, cannabinoid biosynthesis technology and drug development pipeline are the fundamental value drivers of the Company. For more information, visit www.inmedpharma.com

Contact: InMed Pharmaceuticals Inc.

Chris Bogart
SVP, Investor Relations and Corporate Strategy
T: 604.669.7207
E: chris@inmedpharma.com

Cautionary Note Regarding Forward-Looking Information

Forward Looking Statements

This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances.

Additionally, there are known and unknown risk factors which could cause InMed Pharmaceuticals actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein.

All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed Pharmaceuticals disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

These risks and uncertainties include, among others, the possibility that clinical trials will not be successful, or be completed, or confirm earlier clinical trial results, risks associated with obtaining funding from third parties, risks related to the timing and costs of clinical trials and the receipt of regulatory approvals.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.